THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS

THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS

Show other versions (1)

Due to the fact that tumor necrosis factor-а (TNF-а) inhibitors are in wide use, the problem of the safety of therapy with drugs of this group is pressing. The review discusses the data of randomized and observational clinical trials of three drugs of this group (adalimumab, infliximab, and etanerce...

Full description

Bibliographic Details
Main Author: Dmitry Evgenyevich Karateyev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2009-09-01
Series:Современная ревматология
Subjects:
rheumatoid arthritis
adalimumab
infliximab
etanercept
treatment safety
adverse reactions
Online Access:http://mrj.ima-press.net/index.php/mrj/article/view/240

Internet

http://mrj.ima-press.net/index.php/mrj/article/view/240

Similar Items